3D Biomatrix designs and manufactures three-dimensional scaffolds for cellular assays in drug discovery. For a diverse group of customers such as researchers and drug discovery experts, 3D Biomatrix produces high quality products that provide better outcomes. 3D Biomatrix scaffolds have been tested in bone marrow, platelets, thymus and have demonstrated positive results.

Accord Biomaterials, Inc., focuses upon the development of NogenTM catalytic nitric oxide coatings for blood-contacting medical devices. Nogen coatings address serious complications related to clotting and altered healing, improving performance and reducing total costs of critical medical device interventions. Accord collaborates with the University of Michigan and incubator MC3 Corporation and holds an exclusive license to Nogen technology. Privately-held and venture-backed, Accord is committed to accelerating clinical availability of this revolutionary technology.

AFID Therapeutics Inc. defines and delivers advanced chemical and biochemical technologies and strategies and employs them in the design, discovery, delivery, and development of new drugs. Behind the company is an extensive web of synthetic chemistry patents and expertise covering processes and compositions that allow the preparation of very advanced small molecule drugs and new advanced materials for use in their delivery.

Armune BioScience was formed to develop and commercialize high value, protein signature-based diagnostic tests for prostate, lung and breast cancers that will allow physicians and patients to make better treatment decisions.

Aursos (pronounced R-sos)was founded in March of 2007. The Company has licensed technologydeveloped at Michigan Technological University in the laboratory of Dr.Seth Donahue on the family of naturally-occurring parathyroid Hormone(PTH) proteins found in the black bear (Ursus americanus). Thetherapeutic mission of the company is to develop black bear PTH(BB-PTH) 1-34 for the prevention and treatment of osteoporosis.

Avidimer Therapeutics' lead product is a compound that targets diseases while minimizing collateral damage to healthy tissues. Two of the biggest diseases it's looking at targeting are rheumatoid arthritis and cancer.

Biotectix, LLC is working to develop and commercialize bioactive, conductive polymer materials and coatings specifically tailored to enhance a wide variety of implantable medical devices. These novel materials bridge the biotic-abiotic interface, join conductive systems ionically and electronically, and improve MRI compatibility and safety. The Biotectix technology platform also makes it possible to design and create next-generation all-polymer leads that may be grown in the body. Biotectix grew out of research on the use of conducting polymers for biocompatible electrodes led by Drs. David Martin, Sarah Richardson-Burns, and Jeffrey Hendricks at the University of Michigan.

Cielo MedSolutions is a leading provider of healthcare software for ambulatory care providers. Its Cielo ClinicTM enhances the quality of patient care, improves practice revenues, and optimizes practice efficiency, helping health care providers to harness the power of a preventive care and chronic disease management information system. Cielo ClinicTM is based on an all-problem, all-patient patient registry, dynamic clinical decision support and proactive population management.

Compendia Bioscience, Inc. is dedicated to gathering the world's high-throughput biology data, making that data interpretable and applicable in target identification/validation, drug development, and clinical research to ultimately improve the lives of patients. Its flagship product, Oncomine™, integrates and unifies this data so that target expression across thousands of human tumors, hundreds of cancer types and subtypes, and millions of dollars of experiments can be assessed online in seconds. Oncomine enables users to discover and prioritize potential cancer targets and biomarkers, improving efficiency, strengthening product pipelines and increasing the likelihood of success.
EADevices is a southwest Michigan-based medical device company committed to the evolution of minimally invasive surgical procedures, developing technology that would offer early cancer detection for patients whose doctors were leery of performing traditional biopsies.

Emiliem is developing Molecular Targeted Therapeutics (MTTs) for oncology and other indications. MTTs are novel therapeutic agents that target biologically important processes central to the development and progression of cancer and other diseases.
FreeStride Therapeutics Inc. is a company which aims to repurpose therapeutic technology to treat bone density problems in horses. Ann Arbor-based Velcura Therapeutics is licensing its drug technology to Ann Arbor startup FreeStride Therapeutics, which hopes to get the drug approved for the veterinary market within a few years.

MedElute is in preclinical development of a drug-eluting product to treat post-surgical adhesions (scars that form abnormal connections between tissue surfaces) using a highly novel anti-platelet approach. Post-surgical adhesion formation is a natural consequence of surgery, resulting when tissue repairs itself following incision, cauterization, suturing, or other means of trauma.

Nymirum is developing a drug discovery platform that reveals the structure of RNA (ribonucleic acid) and identifies the small molecules that will bind to these structures.

OcuSciences Inc. is working to develop and commercialize the OcuMet™ line of ocular metabolic imaging products. Founded by Victor Elner, M.D., Ph.D. and Howard Petty, Ph.D. at the University of Michigan’s Kellogg Eye Center, OcuSciences has innovated the retinal metabolic analysis (RMA), a novel technique that allows detection of certain eye diseases several years earlier than current clinical methods. The most significant impact of the The OcuMet™ products on current healthcare practice is in the early detection and monitoring of diabetes. Once diagnosed with disease, OcuMet™ helps monitor disease progression and mitigation by treatment.

OtoMedicine, Inc., a biopharmaceutical company founded in 2006, is working to become the leading provider of medicines to prevent, treat, and cure hearing loss. OtoMedicine will commercialize more than two decades of scientific research and technology developed in the laboratories of Dr. Josef Miller at the University of Michigan’s Kresge Hearing Research Institute. OtoMedicine has developed Auraquell™, a specific combination of micronutrients has already been shown to provide significant synergistic protection against noise-induced injury in pre-clinical studies with animal subjects.

Phrixus Pharmaceuticals was created to develop and commercialize Carmeseal™, a novel therapy for the treatment of heart failure in the general population and in patients with Duchenne Muscular Dystrophy.

RealBio Technology, Inc. is developing and commercializing leading edge cell and tissue culture technologies that support the growth, expansion, differentiation, and collection of human and non-human cells.

SensiGen is a biotechnology company focused on gene-based molecular diagnostics. Our mission is to develop and commercialize nucleic acid tests that detect serious diseases earlier, monitor diseases more effectively, and lower overall healthcare costs.
Ultrasound Medical Devices develops advanced algorithms and software for enhanced cardiac ultrasound medical imaging. The company specialized in imaging and advanced sensor technology.

Vestaron Corporation is developing a new generation of insecticides by employing peptides sourced from spiders – insecticides that are ideally suited for the environmentally conscious, twenty-first century. Over 50 unique, spider-venom peptides with novel sites of action have been identified and are being exploited. This patented technology is exclusively licensed to Vestaron
Back to top